

Neither Applicants nor their attorneys make any representation that any information disclosed herein may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103. Moreover, pursuant to 37 C.F.R. § 1.97, the filing of this Information Disclosure Statement shall not be

construed as a representation that a search has been made or as an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.98, this Information Disclosure Statement includes and is accompanied by:


1. A completed copy of Form PTO-1449 listing the patents, publications and other information being submitted for consideration; and
2. A legible copy of each patent, publication and other item of information in written form listed on the enclosed Form PTO-1449, excluding copies of references falling under the prior submission or citation exception of 37 C.F.R. § 1.98(d).

Various patents, publications, and other items of information listed on the accompanying Form PTO-1449 were previously cited by and/or submitted to the U.S. Patent and Trademark Office in Applicant's prior application (App. Serial No. 09/828,645 filed April 5, 2001 for "IMMUNOLOGICAL METHODOLOGY FOR DISCERNING HUMAN PAPILLOMAVIRUS"), which is being relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98(d), copies of these patents, publications, and other items of information are not being submitted with this Statement.




DATED this 11<sup>th</sup> day of February, 2004.

Respectfully submitted,

  
\_\_\_\_\_  
Gary D.E. Pierce  
Attorney for Applicants  
Reg. No.: 38,019

Date: February 11, 2004

PATE PIERCE & BAIRD  
550 Park Side Tower  
215 South State Street  
Salt Lake City, Utah 84111  
Telephone: (801) 530-0330  
Facsimile: (801) 530-5955



<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (use several sheets if necessary)	<b>SERIAL NO.</b> 10/612,818	<b>ATTORNEY DOCKET NO.</b> 3352.2.2
	<b>FILING DATE</b> July 1, 2003	<b>GROUP ART UNIT</b> 1653
	<b>APPLICANT(S):</b> Yao Xiong Hu	

**REFERENCE DESIGNATION****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	6,183,746	Feb. 6, 2001	Urban et al.	424/186.1	10/9/98
	A2	5,932,412	Aug. 3, 1999	Dillner et al.	435/5	9/22/97
	A3	5,629,161	May 13, 1997	Muller et al.	435/7.1	12/23/94
	A4	5,629,146	May 13, 1997	Dillner et al.	435/5	6/25/91
	A5	4,777,239	Oct. 11, 1988	Schoolnik et al.	530/326	7/10/86

**FOREIGN PATENT DOCUMENTS**


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION	
						YES	NO
	A6	WO 91/18294	Nov. 28, 1991	Sweden	G01N 33/569	X	
	A7	EP 0344940	Dec. 12, 1989	European	C07K 7/06	X	
✓	A8	WO 87/01375	Mar. 12, 1987	France	C07K 15/00		X

**NON-PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT (Including Author, Title, Source, and Pertinent Pages)
✓	A9	Anonymous, Cervical cancer, NIH Consensus Statement 1996 Apr 1-3; 14(1):1-38.
✓	A10	Arends et al., Aetiology, pathogenesis, and pathology of cervical neoplasia, Journal of Clinical Pathology 1998; 51:96-103.
✓	A11	Birdsong G.C., Automated rescreening of Pap smears: what are the implications?, Diagnostic Cytopathology, 1996; 13:283-8.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



✓	A12	Borysiewicz et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer, Lancet 1996; 347:1523-7.
✓	A13	Bryan et al., Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle, Journal of Med Virology 1997; 53:185-8.
✓	A14	Chee et al., Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins, Gynecology Oncology 1995; 57:226-231.
✓	A15	Clavel et al., DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR, Journal of Clinical Pathology 1998; 51(1):38-43.
✓	A16	Cox et al., Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, American Journal of Obstetrics and Gynecology 1995; 172:946-54.
	A17	Cuzick et al., A systematic review of the role of human papilloma virus (HPV) testing within a crevical screening programme: summary and conclusions, British Journal of Cancer 2000; 85(5): 561-65.
✓	A18	Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine, Journal of Infectious Diseases 1996; 713: 314-20.
	A19	Dreau et al., Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression, Annals of Surgery 2000; 231(5): 664-71.
✓	A20	Ferenczy et al., Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, American Journal of Obstetrics and Gynecology 1996; 175(3): 651-6.
✓	A21	Frisch et al., Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S., Cancer 2000; 88: 1464-9.
	A22	Fu et al., Human papillomavirus and papillomatosis lesion of female lower genital tract, Infectious Disease Obstetrics and Gynecology 1994; 1: 235-41.
	A23	Fu et al., Diagnosis between condyloma acuminatum and pseudocondyloma in lower female genital tract as determined by a PCR-based method, Chinese Journal of Obstetrics and Gynecology 1994; 29(1): 168-88. [in Chinese; English abstract]
	A24	Gregoire et al., Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma, Journal of the National Cancer Institute 1995; 87(22): 1705-9.
✓	A25	Hagensee et al., Seroprevalence of human papillomavirus type 16 in pregnant women, Obstetrics and Gynecology 1999; 94(5): 653-8.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



✓	A26	Hamsikova et al., Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls, Journal of Infectious Diseases 1994; 170: 1424-31.
✓	A27	Harlan et al., Cervical cancer screening: who is not screened and why?, American Journal of Public Health 1991; 81: 885-91.
✓	A28	Hayward et al., Who gets screened for cervical and breast cancer? Results from a New National Survey, Archives of Internal Medicine 1988; 148: 1117-81.
	A29	Hu YX, Introduction and prospect of application of biogenetic engineering, Guangzhou Medical Journal 1990; 2:8-10. [in Chinese, English title]
✓	A30	Hutchinson et al., Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep™ Processor, American Journal of Clinical Pathology 1994; 101: 215-9.
✓	A31	Jochmus et al., Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies, Molecular and Cellular Probes 1992; 6: 319-25.
✓	A32	Kochel et al., Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products, Virology 1991; 182: 644-54.
✓	A33	Konya et al., Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein, Journal of General Virology 1997; 78: 2615-20.
✓	A34	Lorincz et al., Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types, Obstetrics and Gynecology 1992; 79: 328-37.
✓	A35	Lowy et al., Papillomaviruses: prophylactic vaccine prospects, Biochimica et Biophysica Acta 1998; 1423: M1-8.
	A36	Mellin et al., Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival, International Journal of Cancer (Pred. Oncol.) 2000; 89: 300-4.
	A37	Meschede et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, Journal of Clinical Microbiology 1998; 36(2): 475-80.
✓	A38	Muller et al., Antibodies to the E4, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated disease and in the normal population, Journal of Investigative Dermatology 1995; 104: 138-41.
	A39	Nobbenhuis et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, Lancet 1999; 354: 20-5.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



	A40	Petter et al., Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women, Journal of General Virology 2000; 81: 701-8.
	A41	Pirog et al., Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, American Journal of Pathology 2000; 157(4): 1055-62.
/	A42	Rice et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology 1999; 9: 15-21.
/	A43	Schiffman MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute 1992; 84(6): 394-8.
/	A44	Silins et al., Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6.
/	A45	Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93.
	A46	Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax 1996; 51: 887-93.
	A47	Sugase et al., Distinct manifestations of human papillomavirus in the vagina, International Journal of Cancer 1997; 72: 412-5.
	A48	Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 935-40.
/	A49	Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician 1997; 55: 1813-16.
/	A50	Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology 1999; 189: 12-19.
/	A51	Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association 2000; 283: 81-6.
	A52	Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma, International Journal of Cancer 2000; 85: 815-8.

Z:\ALL CLIENTS\3352 Impact Diagnostics\3352-2-2\3352-2-2 PAT-FIL-IDS 1449 040129.wpd

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).